FDA approves Travere’s Filspari as first drug for the kidney disease FSGSnews2026-04-14T09:02:09+00:00April 14th, 2026|Endpoints News|
Click Therapeutics cuts 27% of workforce after $50M raisenews2026-04-13T21:03:44+00:00April 13th, 2026|Endpoints News|
White House policies are ‘incredibly worrisome’ for small biotechs, Rhythm CEO says news2026-04-13T18:52:23+00:00April 13th, 2026|Endpoints News|
FDA narrows in on search for new biologics and vaccines leadernews2026-04-13T17:35:19+00:00April 13th, 2026|Endpoints News|
Allogene’s first cut of data on ‘off-the-shelf’ CAR-T shows promisenews2026-04-13T15:25:50+00:00April 13th, 2026|Endpoints News|
Neomorph raises $100M for molecular glues; Spyre’s ulcerative colitis datanews2026-04-13T15:19:10+00:00April 13th, 2026|Endpoints News|
Regeneron wades into radiopharma through $40M upfront deal with Telixnews2026-04-13T14:51:29+00:00April 13th, 2026|Endpoints News|
BioNTech’s HER2 ADC succeeds in Phase 2 study, FDA filing plannednews2026-04-13T14:32:17+00:00April 13th, 2026|Endpoints News|
Revolution Medicines’ pancreatic cancer drug doubles survival time in Phase 3news2026-04-13T12:00:21+00:00April 13th, 2026|Endpoints News|
Ideaya’s uveal melanoma drug exceeds success benchmark in late-stage trialnews2026-04-13T10:51:33+00:00April 13th, 2026|Endpoints News|
